NAION and Semaglutide: New Research Findings Recent studies have shed light on a potential link between semaglutide use and an increased risk of Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
SURPASS-CVOT is unique, in that it compares the dual incretin agonist with a GLP-1 RA that has been shown to have cardiovascular benefit in people with type 2 diabetes and high risk ASCVD
At present, the available evidence suggests that both GLP-1 agonist and SGLT2 inhibitors produce unfavourable outcomes, and should be avoided in pregnancy and during lactation
This is believed to be down to body composition, as women typically have a higher body fat percentage and female-specific hormones, which may interact with the drug differently
doi: 10.2337/dc15-1025 Summary Keywords obesity, adiposity, insulin resistance, overweight, weight loss Citation Resnick O, Bril F and Beauchamp G (2025) Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer
Carb-managed to target insulin resistance and stabilize blood sugar
.webp)
